Allinaire Therapeutics

Allinaire Therapeutics is a preclinical-stage biotech focused on a novel, cytokine-targeted approach to treating severe cardiopulmonary diseases, with its lead program aimed at pulmonary arterial hypertension (PAH). The company's core asset is a humanized monoclonal antibody against EMAP II, a pathogenic cytokine implicated in vascular dysfunction, inflammation, and cell injury. Backed by experienced scientific founders and a management team with deep industry expertise, Allinaire is advancing its antibody through preclinical development with the goal of addressing a significant unmet medical need in PAH, where current therapies are largely symptomatic.

Humanized monoclonal antibodies targeting the cytokine EMAP II (Endothelial Monocyte Activating Polypeptide II) to modulate apoptosis, endothelial cell function, and inflammation in cardiopulmonary diseases.

Allinaire competes in a crowded PAH market dominated by large pharma companies (e.g., Johnson & Johnson, United Therapeutics) selling vasodilatory therapies. It faces competition from other biotechs developing next-generation agents targeting pathways beyond vasodilation, such as inflammation, cell proliferation, and metabolism, making clinical differentiation critical.